STOCK TITAN

[8-K] Fluor Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Quantum-Si Incorporated (Nasdaq: QSI) has entered into a registered direct offering to sell 18.2 million shares of Class A common stock at $1.67 per share and pre-funded warrants for up to 11.74 million additional shares at $1.6699 per warrant (exercise price $0.0001). Gross proceeds are expected to total $49.999 million; after the 6 % placement fee to A.G.P./Alliance Global Partners and estimated expenses, net proceeds are projected at $47.0 million.

Following the share issuance (and excluding warrant exercise), Class A shares outstanding will rise from 163.56 million to 181.76 million, increasing total diluted shares to 193.50 million if the pre-funded warrants are fully exercised. Net tangible book value would increase modestly from $1.35 to $1.38 per share, creating an immediate dilution of $0.29 for new investors versus the offering price.

Cash and marketable securities would expand from $232.6 million to $279.4 million, strengthening liquidity without adding debt. Management intends to deploy the funds for (i) continued product development—including the Proteus™ platform, (ii) commercialization and manufacturing scale-up of Platinum™ and Platinum Pro devices, (iii) research & development, and (iv) general corporate purposes such as working capital and cap-ex.

Key structural terms include: insider and officer 60-day lock-up, company 45-day lock-up, pre-funded warrants to mitigate 4.99 %/9.99 % ownership caps, and 20-vote-per-share Class B stock (controlled by founder Dr. Jonathan Rothberg) remaining unchanged. The raise represents roughly 28 % of current Class A float, delivering capital for growth but at the cost of near-term dilution and potential overhang from warrant exercises.

Quantum-Si Incorporated (Nasdaq: QSI) ha avviato un'offerta diretta registrata per vendere 18,2 milioni di azioni di azioni ordinarie di Classe A a 1,67 $ per azione e warrant pre-finanziati per un massimo di 11,74 milioni di azioni aggiuntive a 1,6699 $ per warrant (prezzo di esercizio 0,0001 $). I proventi lordi previsti ammontano a 49,999 milioni di $; dopo la commissione di collocamento del 6% a favore di A.G.P./Alliance Global Partners e le spese stimate, i proventi netti sono stimati intorno a 47,0 milioni di $.

Dopo l'emissione delle azioni (escludendo l'esercizio dei warrant), le azioni di Classe A in circolazione aumenteranno da 163,56 milioni a 181,76 milioni, portando il totale delle azioni diluite a 193,50 milioni se i warrant pre-finanziati saranno esercitati completamente. Il valore contabile tangibile netto aumenterebbe modestamente da 1,35 $ a 1,38 $ per azione, generando una diluizione immediata di 0,29 $ per i nuovi investitori rispetto al prezzo dell'offerta.

La liquidità, composta da contanti e titoli negoziabili, aumenterebbe da 232,6 milioni di $ a 279,4 milioni di $, rafforzando la liquidità senza aumentare il debito. La direzione intende utilizzare i fondi per (i) lo sviluppo continuo del prodotto, incluso la piattaforma Proteus™, (ii) la commercializzazione e l'aumento della capacità produttiva dei dispositivi Platinum™ e Platinum Pro, (iii) ricerca e sviluppo e (iv) scopi aziendali generali come capitale circolante e spese in conto capitale.

I termini strutturali principali includono: lock-up di 60 giorni per insider e dirigenti, lock-up di 45 giorni per la società, warrant pre-finanziati per mitigare i limiti di proprietà del 4,99%/9,99%, e azioni di Classe B con 20 voti per azione (controllate dal fondatore Dr. Jonathan Rothberg) che rimangono invariate. L'aumento rappresenta circa il 28% del flottante attuale di Classe A, fornendo capitale per la crescita ma con il costo di una diluizione a breve termine e un potenziale sovraccarico derivante dall'esercizio dei warrant.

Quantum-Si Incorporated (Nasdaq: QSI) ha iniciado una oferta directa registrada para vender 18,2 millones de acciones ordinarias Clase A a 1,67 $ por acción y warrants prefinanciados para hasta 11,74 millones de acciones adicionales a 1,6699 $ por warrant (precio de ejercicio 0,0001 $). Se esperan ingresos brutos por un total de 49,999 millones de $; después de la comisión de colocación del 6 % a A.G.P./Alliance Global Partners y los gastos estimados, se proyectan ingresos netos de 47,0 millones de $.

Tras la emisión de acciones (excluyendo el ejercicio de los warrants), las acciones Clase A en circulación aumentarán de 163,56 millones a 181,76 millones, elevando el total de acciones diluidas a 193,50 millones si se ejercen completamente los warrants prefinanciados. El valor contable tangible neto aumentaría modestamente de 1,35 $ a 1,38 $ por acción, generando una dilución inmediata de 0,29 $ para los nuevos inversores en comparación con el precio de la oferta.

El efectivo y los valores negociables aumentarían de 232,6 millones de $ a 279,4 millones de $, fortaleciendo la liquidez sin añadir deuda. La dirección planea utilizar los fondos para (i) el desarrollo continuo del producto, incluida la plataforma Proteus™, (ii) la comercialización y ampliación de la fabricación de los dispositivos Platinum™ y Platinum Pro, (iii) investigación y desarrollo, y (iv) fines corporativos generales como capital de trabajo y gastos de capital.

Los términos estructurales clave incluyen: bloqueo de 60 días para insiders y directivos, bloqueo de 45 días para la compañía, warrants prefinanciados para mitigar los límites de propiedad del 4,99 %/9,99 %, y acciones Clase B con 20 votos por acción (controladas por el fundador Dr. Jonathan Rothberg) que permanecen sin cambios. La ampliación representa aproximadamente el 28 % del flotante actual de Clase A, proporcionando capital para el crecimiento pero a costa de una dilución a corto plazo y un posible sobrestock derivado del ejercicio de los warrants.

Quantum-Si Incorporated (나스닥: QSI)는 등록 직접 공모를 통해 클래스 A 보통주 1,820만 주를 주당 1.67달러에, 그리고 행사 가격이 0.0001달러인 선납 워런트로 최대 1,174만 주를 주당 1.6699달러에 판매하기로 했습니다. 총 수익은 4,999만 달러로 예상되며, A.G.P./Alliance Global Partners에 지급되는 6% 배치 수수료와 예상 비용을 제외한 순수익은 4,700만 달러로 추정됩니다.

주식 발행 후(워런트 행사 제외), 클래스 A 발행 주식 수는 1억 6,356만 주에서 1억 8,176만 주로 증가하며, 선납 워런트가 모두 행사될 경우 희석 주식 총수는 1억 9,350만 주로 늘어납니다. 순유형자산 장부가치는 주당 1.35달러에서 1.38달러로 소폭 상승하며, 신규 투자자에게는 공모가 대비 즉각적인 0.29달러 희석 효과가 발생합니다.

현금 및 시장성 증권은 2억 3,260만 달러에서 2억 7,940만 달러로 증가해 부채 없이 유동성을 강화합니다. 경영진은 자금을 (i) Proteus™ 플랫폼을 포함한 제품 개발 지속, (ii) Platinum™ 및 Platinum Pro 장치의 상업화 및 제조 확대, (iii) 연구개발, (iv) 운전자본 및 자본적 지출과 같은 일반 기업 목적에 사용할 계획입니다.

주요 구조적 조건으로는 내부자 및 임원 60일 락업, 회사 45일 락업, 4.99%/9.99% 소유 제한을 완화하는 선납 워런트, 그리고 창립자 Dr. Jonathan Rothberg가 통제하는 주당 20표의 클래스 B 주식이 변함없이 유지되는 점이 포함됩니다. 이번 자금 조달은 현재 클래스 A 유통 주식의 약 28%에 해당하며, 성장 자본을 제공하지만 단기 희석 및 워런트 행사로 인한 잠재적 부담이 따릅니다.

Quantum-Si Incorporated (Nasdaq : QSI) a lancé une offre directe enregistrée pour vendre 18,2 millions d'actions ordinaires de classe A à 1,67 $ par action ainsi que des bons de souscription préfinancés pour jusqu'à 11,74 millions d'actions supplémentaires à 1,6699 $ par bon (prix d'exercice 0,0001 $). Les produits bruts attendus s'élèvent à 49,999 millions de $ ; après une commission de placement de 6 % versée à A.G.P./Alliance Global Partners et les dépenses estimées, les produits nets sont projetés à 47,0 millions de $.

Après l'émission des actions (hors exercice des bons), le nombre d'actions de classe A en circulation passera de 163,56 millions à 181,76 millions, portant le total des actions diluées à 193,50 millions si les bons préfinancés sont entièrement exercés. La valeur comptable tangible nette augmenterait légèrement de 1,35 $ à 1,38 $ par action, créant une dilution immédiate de 0,29 $ pour les nouveaux investisseurs par rapport au prix de l'offre.

La trésorerie et les titres négociables passeraient de 232,6 millions $ à 279,4 millions $, renforçant la liquidité sans augmenter la dette. La direction prévoit d'utiliser les fonds pour (i) le développement continu des produits, y compris la plateforme Proteus™, (ii) la commercialisation et l'augmentation de la production des dispositifs Platinum™ et Platinum Pro, (iii) la recherche et développement, et (iv) des fins générales d'entreprise telles que le fonds de roulement et les dépenses d'investissement.

Les principaux termes structurels incluent : une période de blocage de 60 jours pour les initiés et dirigeants, une période de blocage de 45 jours pour la société, des bons préfinancés pour atténuer les plafonds de propriété de 4,99 %/9,99 %, et des actions de classe B avec 20 voix par action (contrôlées par le fondateur Dr Jonathan Rothberg) qui restent inchangées. Cette levée de fonds représente environ 28 % du flottant actuel de la classe A, fournissant des capitaux pour la croissance mais au prix d'une dilution à court terme et d'une possible surcapacité liée à l'exercice des bons.

Quantum-Si Incorporated (Nasdaq: QSI) hat eine registrierte Direktplatzierung eingeleitet, um 18,2 Millionen Aktien der Klasse A Stammaktien zu je 1,67 $ sowie vorausfinanzierte Warrants für bis zu 11,74 Millionen zusätzliche Aktien zu je 1,6699 $ pro Warrant (Ausübungspreis 0,0001 $) zu verkaufen. Die Bruttoerlöse werden voraussichtlich 49,999 Millionen $ betragen; nach einer Platzierungsgebühr von 6 % an A.G.P./Alliance Global Partners und geschätzten Ausgaben werden die Nettoerlöse auf 47,0 Millionen $ geschätzt.

Nach der Aktienausgabe (ohne Ausübung der Warrants) steigt die Anzahl der ausstehenden Klasse A Aktien von 163,56 Millionen auf 181,76 Millionen, wodurch sich die Gesamtzahl der verwässerten Aktien auf 193,50 Millionen erhöht, falls die vorausfinanzierten Warrants vollständig ausgeübt werden. Der Netto-Buchwert je Aktie würde sich moderat von 1,35 $ auf 1,38 $ erhöhen, was für neue Investoren eine sofortige Verwässerung von 0,29 $ im Vergleich zum Angebotspreis bedeutet.

Barmittel und marktfähige Wertpapiere würden von 232,6 Millionen $ auf 279,4 Millionen $ steigen und die Liquidität stärken, ohne Schulden aufzunehmen. Das Management plant, die Mittel für (i) die weitere Produktentwicklung – einschließlich der Proteus™-Plattform, (ii) die Kommerzialisierung und Skalierung der Produktion der Platinum™ und Platinum Pro Geräte, (iii) Forschung & Entwicklung sowie (iv) allgemeine Unternehmenszwecke wie Betriebskapital und Investitionsausgaben einzusetzen.

Wichtige strukturelle Bedingungen umfassen: 60-tägige Sperrfristen für Insider und Führungskräfte, 45-tägige Sperrfrist für das Unternehmen, vorausfinanzierte Warrants zur Minderung der Eigentumsgrenzen von 4,99 %/9,99 % sowie unveränderte Class-B-Aktien mit 20 Stimmen pro Aktie (kontrolliert vom Gründer Dr. Jonathan Rothberg). Die Kapitalerhöhung entspricht etwa 28 % des aktuellen Class-A-Free-Float und stellt Kapital für Wachstum bereit, allerdings zum Preis einer kurzfristigen Verwässerung und potenziellen Belastung durch die Ausübung der Warrants.

Positive
  • $47 million in net proceeds meaningfully strengthens liquidity without increasing debt obligations.
  • Capital earmarked for Proteus™ platform and broader commercial rollout could accelerate revenue inflection.
  • Cash balance rises to $279 million, providing multi-year operating runway.
  • Transaction structured as registered direct—reduces market risk and expedites funding.
Negative
  • Issuance adds 18 %–28 % dilution to existing Class A shareholders depending on warrant exercise.
  • Offering price is 22 % below the prior closing price, indicating weak demand.
  • Pre-funded warrants create a potential overhang and future selling pressure.
  • Short lock-up periods (60/45 days) limit post-deal supply constraints.
  • 6 % placement fee (~$3 M) increases transaction cost relative to at-the-market alternatives.

Insights

TL;DR – $47 M cash bolsters runway but ~18 % dilution and warrant overhang temper equity upside.

The transaction increases cash reserves to ~$279 M, extending funding horizon for at least two years of R&D and commercial rollout. With no incremental debt, leverage remains low. However, issuing stock 22 % below the prior-day close ($2.14) and adding 28 % more Class A shares signals limited institutional demand and pressures EPS. Pre-funded warrants introduce potential selling pressure once exercised. Short lock-ups (60/45 days) could free additional shares before catalyst data arrives. Overall impact is moderately negative for existing shareholders but credit-positive for liquidity.

TL;DR – Fresh capital secures proteomics platform roadmap; execution on Proteus™ now critical.

Quantum-Si’s pipeline—Platinum™, Platinum Pro, and forthcoming Proteus™—requires heavy investment in reagent manufacturing, software, and global sales support. The $47 M raise, added to $233 M cash, should comfortably cover multi-year development cycles and instrument placements. Competitive landscape (Seer, Nautilus, Bruker MS) is heating; timely commercialization is vital. Investors should watch shipment volumes, consumable pull-through, and gross-margin trajectory as funds are deployed. If management converts cash into recurring consumables revenue, dilution will be offset by faster scaling.

Quantum-Si Incorporated (Nasdaq: QSI) ha avviato un'offerta diretta registrata per vendere 18,2 milioni di azioni di azioni ordinarie di Classe A a 1,67 $ per azione e warrant pre-finanziati per un massimo di 11,74 milioni di azioni aggiuntive a 1,6699 $ per warrant (prezzo di esercizio 0,0001 $). I proventi lordi previsti ammontano a 49,999 milioni di $; dopo la commissione di collocamento del 6% a favore di A.G.P./Alliance Global Partners e le spese stimate, i proventi netti sono stimati intorno a 47,0 milioni di $.

Dopo l'emissione delle azioni (escludendo l'esercizio dei warrant), le azioni di Classe A in circolazione aumenteranno da 163,56 milioni a 181,76 milioni, portando il totale delle azioni diluite a 193,50 milioni se i warrant pre-finanziati saranno esercitati completamente. Il valore contabile tangibile netto aumenterebbe modestamente da 1,35 $ a 1,38 $ per azione, generando una diluizione immediata di 0,29 $ per i nuovi investitori rispetto al prezzo dell'offerta.

La liquidità, composta da contanti e titoli negoziabili, aumenterebbe da 232,6 milioni di $ a 279,4 milioni di $, rafforzando la liquidità senza aumentare il debito. La direzione intende utilizzare i fondi per (i) lo sviluppo continuo del prodotto, incluso la piattaforma Proteus™, (ii) la commercializzazione e l'aumento della capacità produttiva dei dispositivi Platinum™ e Platinum Pro, (iii) ricerca e sviluppo e (iv) scopi aziendali generali come capitale circolante e spese in conto capitale.

I termini strutturali principali includono: lock-up di 60 giorni per insider e dirigenti, lock-up di 45 giorni per la società, warrant pre-finanziati per mitigare i limiti di proprietà del 4,99%/9,99%, e azioni di Classe B con 20 voti per azione (controllate dal fondatore Dr. Jonathan Rothberg) che rimangono invariate. L'aumento rappresenta circa il 28% del flottante attuale di Classe A, fornendo capitale per la crescita ma con il costo di una diluizione a breve termine e un potenziale sovraccarico derivante dall'esercizio dei warrant.

Quantum-Si Incorporated (Nasdaq: QSI) ha iniciado una oferta directa registrada para vender 18,2 millones de acciones ordinarias Clase A a 1,67 $ por acción y warrants prefinanciados para hasta 11,74 millones de acciones adicionales a 1,6699 $ por warrant (precio de ejercicio 0,0001 $). Se esperan ingresos brutos por un total de 49,999 millones de $; después de la comisión de colocación del 6 % a A.G.P./Alliance Global Partners y los gastos estimados, se proyectan ingresos netos de 47,0 millones de $.

Tras la emisión de acciones (excluyendo el ejercicio de los warrants), las acciones Clase A en circulación aumentarán de 163,56 millones a 181,76 millones, elevando el total de acciones diluidas a 193,50 millones si se ejercen completamente los warrants prefinanciados. El valor contable tangible neto aumentaría modestamente de 1,35 $ a 1,38 $ por acción, generando una dilución inmediata de 0,29 $ para los nuevos inversores en comparación con el precio de la oferta.

El efectivo y los valores negociables aumentarían de 232,6 millones de $ a 279,4 millones de $, fortaleciendo la liquidez sin añadir deuda. La dirección planea utilizar los fondos para (i) el desarrollo continuo del producto, incluida la plataforma Proteus™, (ii) la comercialización y ampliación de la fabricación de los dispositivos Platinum™ y Platinum Pro, (iii) investigación y desarrollo, y (iv) fines corporativos generales como capital de trabajo y gastos de capital.

Los términos estructurales clave incluyen: bloqueo de 60 días para insiders y directivos, bloqueo de 45 días para la compañía, warrants prefinanciados para mitigar los límites de propiedad del 4,99 %/9,99 %, y acciones Clase B con 20 votos por acción (controladas por el fundador Dr. Jonathan Rothberg) que permanecen sin cambios. La ampliación representa aproximadamente el 28 % del flotante actual de Clase A, proporcionando capital para el crecimiento pero a costa de una dilución a corto plazo y un posible sobrestock derivado del ejercicio de los warrants.

Quantum-Si Incorporated (나스닥: QSI)는 등록 직접 공모를 통해 클래스 A 보통주 1,820만 주를 주당 1.67달러에, 그리고 행사 가격이 0.0001달러인 선납 워런트로 최대 1,174만 주를 주당 1.6699달러에 판매하기로 했습니다. 총 수익은 4,999만 달러로 예상되며, A.G.P./Alliance Global Partners에 지급되는 6% 배치 수수료와 예상 비용을 제외한 순수익은 4,700만 달러로 추정됩니다.

주식 발행 후(워런트 행사 제외), 클래스 A 발행 주식 수는 1억 6,356만 주에서 1억 8,176만 주로 증가하며, 선납 워런트가 모두 행사될 경우 희석 주식 총수는 1억 9,350만 주로 늘어납니다. 순유형자산 장부가치는 주당 1.35달러에서 1.38달러로 소폭 상승하며, 신규 투자자에게는 공모가 대비 즉각적인 0.29달러 희석 효과가 발생합니다.

현금 및 시장성 증권은 2억 3,260만 달러에서 2억 7,940만 달러로 증가해 부채 없이 유동성을 강화합니다. 경영진은 자금을 (i) Proteus™ 플랫폼을 포함한 제품 개발 지속, (ii) Platinum™ 및 Platinum Pro 장치의 상업화 및 제조 확대, (iii) 연구개발, (iv) 운전자본 및 자본적 지출과 같은 일반 기업 목적에 사용할 계획입니다.

주요 구조적 조건으로는 내부자 및 임원 60일 락업, 회사 45일 락업, 4.99%/9.99% 소유 제한을 완화하는 선납 워런트, 그리고 창립자 Dr. Jonathan Rothberg가 통제하는 주당 20표의 클래스 B 주식이 변함없이 유지되는 점이 포함됩니다. 이번 자금 조달은 현재 클래스 A 유통 주식의 약 28%에 해당하며, 성장 자본을 제공하지만 단기 희석 및 워런트 행사로 인한 잠재적 부담이 따릅니다.

Quantum-Si Incorporated (Nasdaq : QSI) a lancé une offre directe enregistrée pour vendre 18,2 millions d'actions ordinaires de classe A à 1,67 $ par action ainsi que des bons de souscription préfinancés pour jusqu'à 11,74 millions d'actions supplémentaires à 1,6699 $ par bon (prix d'exercice 0,0001 $). Les produits bruts attendus s'élèvent à 49,999 millions de $ ; après une commission de placement de 6 % versée à A.G.P./Alliance Global Partners et les dépenses estimées, les produits nets sont projetés à 47,0 millions de $.

Après l'émission des actions (hors exercice des bons), le nombre d'actions de classe A en circulation passera de 163,56 millions à 181,76 millions, portant le total des actions diluées à 193,50 millions si les bons préfinancés sont entièrement exercés. La valeur comptable tangible nette augmenterait légèrement de 1,35 $ à 1,38 $ par action, créant une dilution immédiate de 0,29 $ pour les nouveaux investisseurs par rapport au prix de l'offre.

La trésorerie et les titres négociables passeraient de 232,6 millions $ à 279,4 millions $, renforçant la liquidité sans augmenter la dette. La direction prévoit d'utiliser les fonds pour (i) le développement continu des produits, y compris la plateforme Proteus™, (ii) la commercialisation et l'augmentation de la production des dispositifs Platinum™ et Platinum Pro, (iii) la recherche et développement, et (iv) des fins générales d'entreprise telles que le fonds de roulement et les dépenses d'investissement.

Les principaux termes structurels incluent : une période de blocage de 60 jours pour les initiés et dirigeants, une période de blocage de 45 jours pour la société, des bons préfinancés pour atténuer les plafonds de propriété de 4,99 %/9,99 %, et des actions de classe B avec 20 voix par action (contrôlées par le fondateur Dr Jonathan Rothberg) qui restent inchangées. Cette levée de fonds représente environ 28 % du flottant actuel de la classe A, fournissant des capitaux pour la croissance mais au prix d'une dilution à court terme et d'une possible surcapacité liée à l'exercice des bons.

Quantum-Si Incorporated (Nasdaq: QSI) hat eine registrierte Direktplatzierung eingeleitet, um 18,2 Millionen Aktien der Klasse A Stammaktien zu je 1,67 $ sowie vorausfinanzierte Warrants für bis zu 11,74 Millionen zusätzliche Aktien zu je 1,6699 $ pro Warrant (Ausübungspreis 0,0001 $) zu verkaufen. Die Bruttoerlöse werden voraussichtlich 49,999 Millionen $ betragen; nach einer Platzierungsgebühr von 6 % an A.G.P./Alliance Global Partners und geschätzten Ausgaben werden die Nettoerlöse auf 47,0 Millionen $ geschätzt.

Nach der Aktienausgabe (ohne Ausübung der Warrants) steigt die Anzahl der ausstehenden Klasse A Aktien von 163,56 Millionen auf 181,76 Millionen, wodurch sich die Gesamtzahl der verwässerten Aktien auf 193,50 Millionen erhöht, falls die vorausfinanzierten Warrants vollständig ausgeübt werden. Der Netto-Buchwert je Aktie würde sich moderat von 1,35 $ auf 1,38 $ erhöhen, was für neue Investoren eine sofortige Verwässerung von 0,29 $ im Vergleich zum Angebotspreis bedeutet.

Barmittel und marktfähige Wertpapiere würden von 232,6 Millionen $ auf 279,4 Millionen $ steigen und die Liquidität stärken, ohne Schulden aufzunehmen. Das Management plant, die Mittel für (i) die weitere Produktentwicklung – einschließlich der Proteus™-Plattform, (ii) die Kommerzialisierung und Skalierung der Produktion der Platinum™ und Platinum Pro Geräte, (iii) Forschung & Entwicklung sowie (iv) allgemeine Unternehmenszwecke wie Betriebskapital und Investitionsausgaben einzusetzen.

Wichtige strukturelle Bedingungen umfassen: 60-tägige Sperrfristen für Insider und Führungskräfte, 45-tägige Sperrfrist für das Unternehmen, vorausfinanzierte Warrants zur Minderung der Eigentumsgrenzen von 4,99 %/9,99 % sowie unveränderte Class-B-Aktien mit 20 Stimmen pro Aktie (kontrolliert vom Gründer Dr. Jonathan Rothberg). Die Kapitalerhöhung entspricht etwa 28 % des aktuellen Class-A-Free-Float und stellt Kapital für Wachstum bereit, allerdings zum Preis einer kurzfristigen Verwässerung und potenziellen Belastung durch die Ausübung der Warrants.

0001124198false00011241982025-07-022025-07-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 2, 2025
 
FLUOR CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware 001-16129 33-0927079
(State or other jurisdiction of
incorporation or organization)
 (Commission File Number) (IRS Employer Identification
Number)
 
6700 Las Colinas Blvd. 
Irving,Texas75039
(Address of principal executive offices) (Zip Code)
 
Registrant’s telephone number, including area code (469) 398-7000

 
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
                  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.01 par value per shareFLRNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
                                         Emerging growth company  
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o





Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously reported on the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 18, 2025, the Board of Directors (the “Board”) of Fluor Corporation (the “Corporation”) appointed Mr. James R. Breuer as Chief Executive Officer of the Corporation, effective May 1, 2025. On July 2, 2025, the Corporation entered into a letter agreement (the “Relocation Agreement”) with Mr. Breuer pursuant to which Mr. Breuer will receive a payment of $750,000 (the “Relocation Assistance Bonus”) to support the relocation of his primary residence to the Dallas-Fort Worth area. Subject to the terms and conditions of the Relocation Agreement, Mr. Breuer will repay 100% of the Relocation Assistance Bonus if (i) he fails to relocate to the Dallas-Fort Worth area by June 30, 2026 or (ii) his employment is terminated prior to 24 months from the date the Relocation Assistance Bonus is paid. The foregoing description is a summary only and is qualified in its entirety by reference to the full text of the Relocation Agreement, which will be filed as an exhibit to the Corporation’s quarterly report on Form 10-Q for the quarter ended September 30, 2025.

In addition, on July 2, 2025, FDEE Consulting, Inc., a wholly owned subsidiary of the Corporation, entered into a Consulting Agreement (the “Consulting Agreement”) with Mr. Joseph L. Brennan, the Corporation’s former Chief Financial Officer, pursuant to which Mr. Brennan will provide advisory and consultation services to the Corporation at a rate of $640 per hour for a period of up to six months beginning July 2, 2025. The foregoing description is a summary only and is qualified in its entirety by reference to the full text of the Consulting Agreement, which will be filed as an exhibit on Form 10-Q for the quarter ended September 30, 2025.
2


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 7, 2025
FLUOR CORPORATION
  
 By:/s/ Kevin B. Hammonds
  Kevin B. Hammonds
  Executive Vice President, Chief Legal Officer and Corporate Secretary

3

FAQ

How much capital will Quantum-Si (QSI) raise in the July 2025 offering?

Gross proceeds are $49.999 million; net proceeds after fees and expenses are expected to be ~$47.0 million.

What will QSI use the new funds for?

Management plans to fund Proteus™ development, expand commercialization of Platinum™ instruments, support manufacturing scale-up, R&D, and general corporate purposes.

How much shareholder dilution results from the transaction?

Class A shares outstanding rise from 163.6 M to 181.8 M (or 193.5 M if pre-funded warrants are exercised), implying 18 %–28 % dilution.

What is the impact on Quantum-Si’s balance sheet?

Cash and marketable securities increase to $279.4 million, while long-term debt stays at $11.7 million, improving liquidity metrics.

When will the offering close and who is the placement agent?

Closing is expected on or about July 8, 2025; A.G.P./Alliance Global Partners is acting as sole placement agent for a 6 % fee.

Do the pre-funded warrants trade on Nasdaq?

No. The warrants are unlisted; there is no established public market for them.
Fluor Corp

NYSE:FLR

FLR Rankings

FLR Latest News

FLR Latest SEC Filings

FLR Stock Data

8.69B
161.63M
1.75%
95.7%
4.4%
Engineering & Construction
Heavy Construction Other Than Bldg Const - Contractors
Link
United States
IRVING